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<200 cells/ml) when they are diagnosed with a URI caused
by inﬂuenza or RSV to prevent progression to pneumonia and
possible death.328 14
pdate on infections in transplant recipients
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Tropical infections in solid organ transplant recipients
re an increasing problem worldwide. This increase is the
esult of several factors. Firstly, the number of coun-
ries with transplantation programs is increasing and now
ncludes countries in the tropics. Secondly, there has been an
ncrease in immigration and international travel worldwide.
nd ﬁnally, commercial transplantation is a growing emer-
ent problem. Chagas disease, strongyloidiasis and less so
uberculosis, are only a few of the infections that have tra-
itionally been considered to be limited to tropical regions,
ut that are common enough to pose a challenge in the
anagement of transplant recipients or candidates world-
ide. Evidence based recommendations on the prevention
nd treatment of these diseases in the transplant popula-
ion is scarce, and usually the result of small retrospective
tudies.
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Six polyomaviruses (PyV) infect humans, but show dif-
erent seroprevalence rates i.e. BK 82%, JC 58%, KI 69%,
U 55%, MC 42% and SV40 <5%. BK and JC PyV are known
o persist in the renourinary tract with asymptomatic uri-
ary shedding in 7% and 19% of healthy adults, respectively.
I and WU PyV can be detected in less than 2% of res-
iratory secretions, but may cause bronchitis/pneumonia
n immuno-compromized patients. MC PyV integration has
een linked to Merkel carcinoma in immunocompromized,
ut MC genomes can also be detected in 38% of healthy
kin swabs. BK PyV is linked to two major complications in
ransplant recipients, polyomavirus-associated nephropathy
PyVAN) and polyomavirus-associated hemorrhagic cystitis
PyVHC). PyVAN and PyVHC have been encountered in a vari-
ty of immunodeﬁcient patients, but most cases of PyVAN
rise in kidney transplant patients at rates of 1-10%, while
yVHC preferentially affects allogeneic hematopoietic stem
ell transplant patients at rates of 5-15%. BKV has been
ess frequently associated with other pathologies such as
reteric stenosis, pneumonitis, hemophagocytic syndrome,
ncephalitis, retinitis, and polyomavirus-associated multi-
ocal leukoencephalopathy (PyVML), a complication of the
entral nervous system mostly caused by the closely related
C PyV. PyVAN is rare in non-kidney transplant recipients,
espite similar or even higher intensity of immunosuppres-
ion. The objective of this presentation is to provide an
dternational Congress on Infectious Diseases (ICID) Abstracts
pdate on PyV in kidney transplantation and highlight the
urrent recommendations of the AST-ID and KDIGO focussing
K and PyVAN regarding screening, diagnosis and manage-
ent.
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Inﬂuenza, parainﬂuenza, respiratory syncytial virus and
icornavirus infections are common causes of upper respi-
atory infection. For many years these viral infections were
onsidered to be of minimal concern in patients with can-
er. However, during the past 20 years, these viruses have
een recognized as a possible cause of serious infections
n patients undergoing hematopoietic stem cell transplan-
ation (HSCT) or therapy for hematologic malignancies,
specially acute leukemia. Some of these patients have only
RIs from which they recover uneventfully, but others have
nfections that progress to pneumonia, which can be fatal.
mportant advances have been made in recent years in the
anagement of these infections, including the development
f rapid diagnostic tests and the discovery of therapeu-
ic agents for some of these infections. Many studies from
ifferent institutions, including ours, looked at their experi-
nce with these infections to determine their impact on this
roup of patients, most of who were immunocompromised
nd acquired their infections in the community. Several
mportant predisposing factors for these infections have
een identiﬁed in HSCT recipients and patients with hema-
ological malignancies. These include age >65 years, severe
eutropenia, severe lymphopenia, allogeneic transplanta-
ion, transplant conditioning regimen, graft versus host
isease and adrenal corticosteroid therapy. HSCT recipients
re at greatest risk within the ﬁrst 100 days post-transplant.
everal studies have suggested that aerosolized ribavirin is
ffective for the therapy of RSV pneumonia in HSCT recip-
ents, especially when administered with immunoglobulins,
lthough the number of cases has been small. In summary,
here is some evidence to suggest that it may be beneﬁ-
ial to administer therapy routinely to HSCT recipients and
atients with hematologic malignancies who have known
redisposing factors for pneumonias (i.e. age>65 years, ALCoi:10.1016/j.ijid.2010.02.2221
